The prognosis for COL1A1–PDGFB fusion uterine sarcomas does not seem optimistic so far, as the current clinical evidence, long-term follow-up of these patients, and more clinical analyses with bigger sample size are urgently needed to better study the prognosis of this particularly rare type of uterine sarcoma. This evidence concerns the gene COL1A1 and uterine corpus sarcoma.